$11.03
9.10% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Mesoblast Limited Sponsored ADR Stock price

$11.03
+2.45 28.55% 1M
+2.86 35.01% 6M
+8.83 401.36% YTD
+8.29 302.55% 1Y
-1.73 13.56% 3Y
-1.33 10.76% 5Y
-24.29 68.77% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.92 9.10%
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Key metrics

Market capitalization $1.26b
Enterprise Value $1.31b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 223.22
P/S ratio (TTM) P/S ratio 213.72
P/B ratio (TTM) P/B ratio 2.62
Revenue growth (TTM) Revenue growth -24.47%
Revenue (TTM) Revenue $5.89m
EBIT (operating result TTM) EBIT $-58.69m
Free Cash Flow (TTM) Free Cash Flow $-55.76m
Cash position $71.32m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 73.47
EV/Sales forward 76.73
Short interest 1.58%
Show more

Is Mesoblast Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy
100%

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
5.89 5.89
0% 0%
100%
- Direct Costs 16 16
0% 0%
266%
-9.79 -9.79
33% 33%
-166%
- Selling and Administrative Expenses 19 19
20% 20%
321%
- Research and Development Expense 25 25
0% 0%
430%
-54 -54
-
-917%
- Depreciation and Amortization 4.66 4.66
-
79%
EBIT (Operating Income) EBIT -59 -59
0% 0%
-997%
Net Profit -88 -88
0% 0%
-1,489%

In millions USD.

Don't miss a Thing! We will send you all news about Mesoblast Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mesoblast Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
27 days ago
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2024.
Positive
Seeking Alpha
about 2 months ago
Mesoblast Limited is advancing innovative cellular therapies, with Remestemcel-L for pediatric SR-aGVHD nearing FDA approval and a PDUFA date set for January 2025. Positive Phase 3 results indicate that Remestemcel-L significantly improves response rates and survival in pediatric patients. Additionally, Mesoblast's pipeline includes late-stage therapies for chronic low back pain and heart failu...
Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George (“Investor”) for issue, at its sole discretion, up to US$50.0 million (A$72.7 million) convertible notes on approv...
More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today